Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial

@article{Caraceni2018LongtermAA,
  title={Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial},
  author={Paolo Caraceni and Oliviero Riggio and Paolo Angeli and Carlo Alessandria and Sergio Neri and Francesco Giuseppe Foschi and Fabio Levantesi and Aldo Airoldi and Sergio Boccia and Gianluca Svegliati-Baroni and Stefano Fagiuoli and Roberto Giulio Romanelli and Raffaele Cozzolongo and Vito Di Marco and Vincenzo Sangiovanni and Filomena Morisco and Pierluigi Toniutto and Annalisa Tortora and Rosanna De Marco and Mario Angelico and Irene Cacciola and Gianfranco Elia and Alessandro Federico and Sara Massironi and Riccardo Guarisco and Alessandra Galioto and Giorgio Ballardini and Maria Rendina and Silvia Nardelli and Salvatore Piano and Chiara Elia and Loredana Prestianni and Federica Mirici Cappa and Lucia Cesarini and Loredana Simone and Chiara Pasquale and Marta Cavallin and Alida Andrealli and Federica Fidone and Matteo Ruggeri and Andrea Roncadori and Maurizio Baldassarre and Manuel Tufoni and Giacomo Zaccherini and Mauro Bernardi and Marco Domenicali and Ferdinando Antonino Giannone and Manuela Merli and Stefania Gioia and Silvano Fasolato and Antonietta Sticca and Daniela Campion and Alessandro Risso and Giorgio Maria Saracco and Daniela Maiorca and Agostino Rizzotto and Arianna Lanzi and Elga Neri and Anna Visani and Antonio Mastroianni and Alberto Battista Alberti and Chiara Mazzarelli and Marcello Vangeli and Marco Marzioni and Francesca Capretti and Alba Kostandini and Giulia Magini and Maria Colpani and Giacomo Laffi and Tommaso Gabbani and Maria Marsico and Marianna Zappimbulso and Josephine M. Petruzzi and Vincenza Calvaruso and Giovanni Parrella and Nicola Caporaso and Francesco Auriemma and Maria Guarino and Fabio Pugliese and Antonio Gasbarrini and Pietro Leo and Francesco De Leonardis and Alessandra Pecchioli and Piera Rossi and Giovanni Raimondo and Elisa Negri and Marcello Dallio and Carmelina Loguercio and Dario Conte and Natascia Celli and Roberto Bringiotti and Nicola Castellaneta and Francesco Salerno},
  journal={The Lancet},
  year={2018},
  volume={391},
  pages={2417-2429}
}
A Randomized Trial of Albumin Infusions in Hospitalized Patients with Cirrhosis.
TLDR
In patients hospitalized with decompensated cirrhosis, albumin infusions to increase the albumin level to a target of 30 g per liter or more was not more beneficial than the current standard care in the United Kingdom.
Effect of albumin administration on outcomes in hypoalbuminemic patients hospitalized with community-acquired pneumonia (ALBUCAP): a prospective, randomized, phase III clinical controlled trial—a trial protocol
TLDR
This randomized trial aims to assess whether the administration of albumin in hypoalbuminemic patients with CAP increases the proportion of clinically stable patients at day 5 compared with the standard of care alone, and if this randomized trial confirms the hypothesis, it should lead to a change in current clinical practice for the management of hypo Albuminemic Patients with CAP.
Albumin administration in patients with decompensated liver cirrhosis: a meta-analytic update.
TLDR
Evidence is provided that LTA administration is significantly effective in reducing the mortality of liver cirrhosis compared to SMT and albumin administration was also shown to reduce the occurrence of ascites, renal failure and hepatic encephalopathy as complications of liver Cirrhosis.
Albumin Administration is Efficacious in the Management of Patients with Cirrhosis: A Systematic Review of the Literature
TLDR
Based on the included evidence, albumin is superior at preventing and controlling the incidence of cirrhosis complications vs other plasma expanders and long-term administration of albumin should be considered in some patients.
Effects of Albumin on Survival after a Hepatic Encephalopathy Episode: Randomized Double-Blind Trial and Meta-Analysis
TLDR
Repeated doses of albumin might be beneficial for patient’s survival as an add-on therapy after an HE episode, but an adequately powered trial is needed.
Treatment for ascites in adults with decompensated liver cirrhosis: a network meta-analysis.
TLDR
There is considerable uncertainty about whether interventions for ascites in people with decompensated liver cirrhosis decrease mortality, adverse events, or liver transplantation compared to paracentesis plus fluid replacement in people receiving different interventions.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 37 REFERENCES
Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial.
TLDR
Long-term albumin administration after first-onset ascites significantly improves patients' survival and decreases the risk of ascites recurrence.
Treatment for ascites in adults with decompensated liver cirrhosis: a network meta-analysis.
TLDR
There is considerable uncertainty about whether interventions for ascites in people with decompensated liver cirrhosis decrease mortality, adverse events, or liver transplantation compared to paracentesis plus fluid replacement in people receiving different interventions.
The risk of AKI in patients treated with intravenous solutions containing hydroxyethyl starch.
  • A. Shaw, J. Kellum
  • Medicine
    Clinical journal of the American Society of Nephrology : CJASN
  • 2013
TLDR
In this brief review, the published literature on the role of hydroxyethyl starch solutions in AKI is considered, with particular emphasis on two large recent randomized clinical trials conducted in Europe and Australia.
Compensated cirrhosis: Natural history and prognostic factors
TLDR
To investigate the natural history of compensated cirrhosis, 293 consecutive patients without previous major complications were studied in terms of morbidity and survival and a prognostic index was constructed that allows calculation of the estimated survival probability.
The management of ascites in cirrhosis: Report on the consensus conference of the international Ascites club
TLDR
The International Ascites Club, representing the spectrum of clinical practice from North America to Europe, have developed guidelines by consensus in the management of cirrhotic ascites from the early ascitic stage to the stage of refractory ascites.
Albumin: Pathophysiologic basis of its role in the treatment of cirrhosis and its complications
TLDR
Its role is being investigated in a large number of indications, which rely on its volume and nonvolume expansion functions such as stroke, severe sepsis, Alzheimer's disease, malaria, burns, and ovarian hyperstimulation syndrome.
...
1
2
3
4
...